New discovery may lead to effective prevention and treatment of graft-versus-host disease

A new discovery in mice may lead to new treatments that could make bone marrow transplants more likely to succeed and to be significantly less dangerous. According to new research findings published in the Journal of Leukocyte Biology Brazilian scientists may have found a way to prevent the immune system from attacking transplant grafts and damaging the host's own cells after a bone marrow transplant.

Specifically, they found that a receptor for a mediator of the , known as platelet activating factor plays a crucial role in the development of graft-versus-host disease. Platelet activating factor receptor appears to contribute to the attraction of that lead to graft-versus-host disease. When this mechanism was blocked, there was reduced tissue damage and mortality.

"Platelet activating factor receptor antagonists may decrease suffering caused by graft-versus-host disease in patients undergoing ," said Vanessa Pinho, Ph.D., a researcher involved in the work from the Departamento de Morfologia, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais in Brazil. "As graft-versus-host disease also may decrease quality of life, patients treated with platelet activating factor may live longer and with better quality of life."

To make this discovery, scientists induced graft-versus-host disease by transferring cells between mice which were genetically incompatible. In mice subjected to graft-versus-host disease, there was significant injury to target organs, especially the liver and the intestine. In mice that received cells from genetically modified mice bred to not have platelet activating factor receptors, or in mice treated with platelet activating factor receptor antagonist, there was reduced tissue injury and reduced lethality.

" is one of the biggest risks of any transplant procedure, and this study sheds a new light on a receptor and pathway amenable to therapeutic intervention to reduce the serious complication of graft-versus-host disease," said John Wherry, Ph.D., Deputy Editor of the . "The next step is to take these observations from the lab and see if the potential suggested by studies in mice hold true in humans with disease."

More information: Marina G. M. Castor, Bárbara M. Rezende, Carolina B. Resende, Priscila T. T. Bernardes, Daniel isalpino, Angélica T. Vieira, Danielle G. Souza, Tarcília A. Silva, Mauro M. Teixeira, and Vanessa Pinho. Platelet-activating factor receptor plays a role in the pathogenesis of graft-versus-host disease by regulating leukocyte recruitment, tissue injury, and lethality. J Leukoc Biol. April 2012 91: 629-639; doi:10.1189/jlb.1111561

add to favorites email to friend print save as pdf

Related Stories

Cancer drug shows promise against graft vs. host disease

Jul 10, 2008

A new University of Michigan study in mice suggests that a drug recently approved to fight cancer tumors is also able to reduce the effects of graft-versus-host disease, a common and sometimes fatal complication ...

Recommended for you

Global Ebola toll rises to 5,689: WHO

4 hours ago

The World Health Organization said Thursday that the global death toll from the Ebola virus had increased to 5,689 out of a total of 15,935 cases of infection, mainly in western Africa.

Ebola vaccine promising in first human trials

15 hours ago

Researchers say they're a step closer to developing an Ebola vaccine, with a Phase 1 trial showing promising results, but it will be months at the earliest before it can be used in the field.

At one month, US Ebola monitors finding no cases

17 hours ago

The U.S. program that requires weeks of monitoring for travelers from African countries with Ebola reaches the one-month mark Thursday. And so far, no cases of the disease have turned up.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.